Compare Johnson & Johnson (JNJ) vs Realty Income Corp (O) Price & Performance

Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.

The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.

Realty Income (O) trades at $65.04, down 1.02% today, near the analyst consensus price target of $67.50. The stock shows a bullish technical setup with strong moving average signals, though RSI levels suggest mild overbought conditions. Recent earnings have missed expectations for three consecutive quarters, but revenue growth remains steady, rising to $5.75B in 2025. The company maintains a high dividend yield with consistent payouts, supported by robust operating cash flow of $4.0B.

Outlook is cautiously optimistic with a solid dividend profile and expansion through partnerships, but elevated P/E of 53.86 and recent earnings misses pose valuation and execution risks. Debt levels have increased, with debt-to-asset ratio reaching 39.93% in 2025, adding financial leverage concerns. Analyst sentiment is mixed with 41% buy ratings, reflecting balanced views on growth potential versus rich valuations.